The extraordinary plasticity of glioma cells allows them to contribute to different cellular compartments in the tumor vessels, reinforcing the vascular architecture. Recently, it was revealed that targeting glioma-derived pericytes, which represent a big percentage of the mural cell population in aggressive tumors, increases the permeability of the vessels and improves chemotherapy efficiency. However, the molecular determinants of this transdifferentiation process have not been elucidated. Here, we show that mutations in EGFR (epidermal growth factor receptor) stimulate the capacity of glioma cells to function as pericytes in a BMX (bone marrow and X-linked)/SOX9 dependent manner. The subsequent activation of PDGFR (platelet derived growth factor receptor beta) in the vessel walls of EGFR mutant gliomas stabilize the vasculature and facilitates the recruitment of immune cells. These changes in the tumor microenvironment confer a growth advantage to the tumors, although it also makes them particularly sensitive to pericyte-targeting molecules such as ibrutinib or sunitinib. In the absence of EGFR mutations, high-grade gliomas are enriched in blood vessels too but they show a highly disrupted blood-brain-barrier due to the decreased BMX/SOX9 activation and pericyte coverage, which lead to poor oxygenation, necrosis and hypoxia. Here, we identify EGFR mutations as key regulators of the glioma-to-pericyte transdifferentiation, highlighting the intricate relation between the tumor cells and their vascular and immune microenvironment.Our results lay the foundations for a vascular dependent stratification of gliomas and suggest different therapeutic vulnerabilities depending on the genetic status of EGFR, which defines the vascular and the immune landscape of the tumors.